Earlier this year, Gilead Sciences, a California-based pharmaceutical company, made the headlines for an unusual, positive move in the fraught property rights space. It entered into a license agreement with seven Indian pharmaceutical companies to manufacture lower cost versions of Sovaldi, its popular Hepatitis C drug